In this trial, ziftomenib, a menin-MLL(KMT2A) inhibitor, will be tested in patients for the first time. The trial includes a Main Study and four sub-studies. In the Main Study (including Phase 1a, Phase 1b, and Phase 2 portions), ziftomenib will be evaluated in patie...
- Leukemia, Myeloid, Acute
- Leukemia, Biphenotypic, Acute
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Hematologic Neoplasms
- Leukemia
Age: 18 years - 66+
Gender: All